Published studies of single-agent thalidomide to treat relapsed/refractory myeloma
Reference . | Study type . | Centers, no. . | Patients, no. . | Dose used, mg/d . | Median age, years (range) . | Response rate, % . |
|---|---|---|---|---|---|---|
| Barlogie et al5 | Prospective, phase 2 | 1 | 169 | 200-800 | 40% > 60 | 37* |
| Yakoub-Agha et al13 | Retrospective, cohort | 10 | 83 | 50-800 | 64 (40-81) | 66* |
| Neben et al6 | Prospective, phase 2 | 1 | 54 | 100-400 | 57 (34-79) | 57* |
| Hus et al8 | Prospective, phase 2 | 3 | 53 | 100-400 | 63 (32-79) | 51* |
| Bertolini et al4 | Prospective, phase 2 | 1 | 17 | 100-400 | 66 (55-80) | 41* |
| Kneller et al9 | Prospective, phase 2 | 1 | 17 | 200-800 | 53 (44-68) | 64 |
| Rajkumar et al10 | Prospective, phase 2 | 1 | 16 | 200-800 | 64 (—) | 25 |
| Juliusson et al3 | Retrospective, cohort | 5 | 23 | 200-800 | 61 (44-78) | 43 |
| Blade et al7 | Retrospective, cohort | 1 | 23 | 200-800 | 72 (40-83) | 52* |
| Tosi et al12 | Retrospective, cohort | 1 | 11 | 100-800 | 55 (42-60) | 72* |
Reference . | Study type . | Centers, no. . | Patients, no. . | Dose used, mg/d . | Median age, years (range) . | Response rate, % . |
|---|---|---|---|---|---|---|
| Barlogie et al5 | Prospective, phase 2 | 1 | 169 | 200-800 | 40% > 60 | 37* |
| Yakoub-Agha et al13 | Retrospective, cohort | 10 | 83 | 50-800 | 64 (40-81) | 66* |
| Neben et al6 | Prospective, phase 2 | 1 | 54 | 100-400 | 57 (34-79) | 57* |
| Hus et al8 | Prospective, phase 2 | 3 | 53 | 100-400 | 63 (32-79) | 51* |
| Bertolini et al4 | Prospective, phase 2 | 1 | 17 | 100-400 | 66 (55-80) | 41* |
| Kneller et al9 | Prospective, phase 2 | 1 | 17 | 200-800 | 53 (44-68) | 64 |
| Rajkumar et al10 | Prospective, phase 2 | 1 | 16 | 200-800 | 64 (—) | 25 |
| Juliusson et al3 | Retrospective, cohort | 5 | 23 | 200-800 | 61 (44-78) | 43 |
| Blade et al7 | Retrospective, cohort | 1 | 23 | 200-800 | 72 (40-83) | 52* |
| Tosi et al12 | Retrospective, cohort | 1 | 11 | 100-800 | 55 (42-60) | 72* |
— indicates no range available.
Response rate included minor responses exceeding 25% reduction from pretreatment M protein.